atropine
Enable an agent to identify atropine, assess evidence about its material state and biological activity, and determine which handling or use decisions require product-specific authority.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
recalled by Codex without web access - no source was read
Researched by: Codex
Purpose and description
Enable an agent to identify atropine, assess evidence about its material state and biological activity, and determine which handling or use decisions require product-specific authority.
Atropine is a tropane alkaloid consisting of a racemic mixture of hyoscyamine enantiomers that competitively antagonizes muscarinic acetylcholine receptors.
It can be Match an asserted atropine identity against chemical-form and stereochemical evidence.; Compare atropine content across materials after verifying salt, hydrate and reporting basis.; Flag unresolved identity, impurity or stability evidence for analytical review.; Connect a material to the applicable specification, safety information and product label.; Distinguish evidence of muscarinic antagonism from evidence supporting a particular clinical use..
Distinguishing features
Require evidence of racemic hyoscyamine composition to distinguish atropine from an isolated hyoscyamine enantiomer; a shared molecular formula is insufficient. Reference: [PubChem atropine](https://pubchem.ncbi.nlm.nih.gov/compound/Atropine).
Check counterion and hydration information before treating atropine free base and atropine sulfate monohydrate as the same weighed material.
Use structure-sensitive identification to distinguish atropine from related tropane alkaloids such as scopolamine; plant origin or antimuscarinic activity alone cannot identify it.
Distinguish an atropine-containing formulation or botanical mixture from the substance itself by recording other constituents and the analytical basis for atropine identification.
Scope
+ Chemical identity and racemic stereochemical composition
+ Free-base, salt and hydration-state distinctions
+ Atropine content, analytical identity, impurities and degradation
+ Muscarinic antagonism and boundaries of biological effects
+ Substance-specific handling and links to formulation-specific requirements
- Hyoscyamine and scopolamine as independently modelled substances
- Atropine-producing plants and botanical extracts as whole organisms or mixtures
- Finished medicinal products, packaging and delivery devices
- Patient diagnosis, prescribing and dosing protocols
- Poisoning events and complete emergency treatment pathways
Characteristics
- Stereochemical composition
- Enantiomer fractions or ratio, with method and uncertainty Tests the racemic identity and prevents conflation with isolated hyoscyamine.
- Chemical form
- Free base; named salt with stoichiometry; specified hydrate; unresolved Determines what a mass, identifier or material specification actually describes.
- Atropine assay
- % mass fraction or mg/mL, explicitly stating free-base or salt basis Makes content comparisons interpretable across solids and formulations.
- Related-substance profile
- Named impurity concentrations in %, mg/g or another declared unit, with detection limits Separates atropine content from accompanying alkaloids and degradation products.
- Material condition
- Conforms to stated specification; degraded; contaminated; unassessed Supports a decision about whether the material remains suitable for its declared purpose.
- Biological target
- Muscarinic receptor target linked to assay, endpoint and biological system Connects identity to measured activity without turning an assay result into a treatment claim.
- Formulation participation
- Ingredient of a specified product, with strength basis and labelled route Keeps medicinal-product permissions attached to the product that establishes them.
- Storage and exposure history
- Recorded temperature, light, moisture and opening history compared with applicable requirements Supports review of stability evidence and potential excursions.
Where this came from
wikidata · CC0 1.0
Also registered as vr.tr.atropine
Drafted structure
Bundle to layer to finding to question, as the second pass will find it: 6 bundles · 11 layers · 19 findings · 29 questions.
Chemical identity Establish what the name atropine denotes and which material forms instantiate it.
A name match can conceal differences in stereochemistry, counterion and hydration.
Racemic identity
Separate atropine from individual hyoscyamine enantiomers and related alkaloids.
Stereochemistry defines atropine
Atropine denotes racemic hyoscyamine; identity evidence must preserve that distinction. Reference: [PubChem atropine](https://pubchem.ncbi.nlm.nih.gov/compound/Atropine).
- Does the cited chemical record explicitly represent the racemate? definition
- What enantiomer-resolving evidence supports identification of this sample as atropine? measurement
Base, salts and hydrates
Track chemical form without creating a duplicate model for each product presentation.
Form-specific identity
Represent counterion, stoichiometry and hydration explicitly wherever a record describes a salt rather than atropine free base.
- Does the identifier refer to atropine free base, a salt or a particular hydrate? boundary
- Which certificate or analytical record establishes counterion and water content? provenance
Origin and analytical confirmation Separate reported origin from demonstrated atropine identity and composition.
Botanical association and nonspecific alkaloid measurements cannot establish a pure racemic substance.
Origin and stereochemical history
Record sourcing and processing evidence relevant to the observed enantiomer composition.
Origin does not establish racemate
Keep plant association, extraction history and confirmed racemic composition as separate assertions.
- Was the material obtained through botanical extraction, synthesis or an undocumented route? provenance
- What evidence distinguishes its initial stereochemical composition from changes during processing or analysis? provenance
Selective identification
Assess whether analytical methods distinguish atropine from neighbouring chemical identities.
Method selectivity
Record whether an assay resolves related tropane alkaloids and enantiomers rather than reporting an undifferentiated signal.
- Which reference standard and analytical method support the atropine assignment? provenance
- Can the method distinguish atropine from scopolamine, isolated hyoscyamine and relevant impurities? measurement
Content and material integrity Make atropine quantity and fitness interpretable across chemical forms and sample conditions.
An unqualified strength or purity value can misrepresent both available atropine and material quality.
Assay reporting basis
Attach every content value to the chemical entity and preparation basis being measured.
Content needs a basis
Specify whether content is expressed as atropine free base or a named salt, and whether solid-material results use an as-received or corrected basis.
- What entity, unit and moisture correction does the reported assay use? measurement
- Are salt stoichiometry, hydration and concentration conventions sufficiently established to compare these quantities? action
Impurities and stability
Relate compositional changes to the specification and stability evidence for the actual material.
Integrity requires specific evidence
Assess related alkaloids and degradation products using applicable methods and limits; appearance alone does not establish atropine integrity.
- Which impurities and degradation products does the applicable specification require the assay to resolve? measurement
- What stability evidence supports acceptance after the recorded storage conditions or excursions? action
Muscarinic activity and boundaries Represent atropine's pharmacological action with explicit limits on interpretation.
A receptor mechanism does not establish every claimed physiological outcome or treatment capability.
Receptor action
Connect atropine to target-specific evidence.
Muscarinic antagonism
Atropine is a competitive, reversible muscarinic receptor antagonist. Reference: [PubChem atropine](https://pubchem.ncbi.nlm.nih.gov/compound/Atropine).
- Which receptor subtype, biological system and endpoint does the activity evidence address? measurement
- Was activity measured for racemic atropine, an isolated enantiomer or a formulation? boundary
Effect and treatment limits
Separate receptor blockade from broader claims about poisoning reversal and clinical benefit.
Antidote claim has limits
A cited injection label specifies blockade of severe muscarinic effects, including in certain poisonings; preserve that boundary when recording antidotal use. Reference: [DailyMed atropine sulfate label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=423fc064-57cb-8308-e063-6394a90a2617&version=1).
- Which claimed effect is supported by muscarinic blockade, and which requires separate mechanistic evidence? boundary
- Does a poisoning-use statement distinguish symptom control from enzyme reactivation and other treatment requirements? boundary
Formulation and handling decisions Connect atropine material to the evidence governing a proposed use or handling action.
Substance identity alone cannot establish route suitability, product interchangeability or storage requirements.
Product context
Keep formulation-dependent properties attached to a specific medicinal product.
Route belongs to product
Record labelled route, strength, excipients and relevant quality requirements through a product relation rather than treating them as universal atropine properties.
- Which product label establishes the intended route and strength basis? provenance
- What formulation and quality evidence is required before considering this material suitable for the proposed use? action
Exposure and storage controls
Resolve handling decisions against the actual atropine form, concentration and preparation.
Controls follow material context
Attach handling, storage and disposal requirements to the relevant safety data sheet, specification or product label, including its revision.
- Which safety document covers this chemical form, concentration and physical presentation? provenance
- Do recorded exposure or storage conditions require containment, quarantine or further assessment under that document? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- This describes the chemical substance and its principal medicinal uses, not a specific pharmaceutical product.
- Pharmacopoeial editions, approved indications and regional regulatory status require verification; no sources were consulted.
- Salt form, hydration state and whether quantities refer to salt or free-base equivalents must be checked when comparing product specifications.
- Which of these check these first hold for the sense of atropine this model covers, and on what evidence? provenance
Kinds and varieties
Recalled without web access and unsourced; every item is a lead to verify.
- Atropine free base
- Atropine sulfate
- Which of these kinds and varieties hold for the sense of atropine this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- CAS Registry Number - 51-55-8 - Identifies atropine free base; salts have separate identifiers.
- Molecular formula - C17H23NO3 - Formula of the free base.
- ATC - A03BA01 - WHO classification for atropine in the belladonna alkaloid group.
- ATC - S01FA01 - WHO classification for ophthalmic atropine.
- Which of these identifiers and schemes hold for the sense of atropine this model covers, and on what evidence? provenance
Standards and regulation
Recalled without web access and unsourced; every item is a lead to verify.
- United States Pharmacopeia-National Formulary, published by the United States Pharmacopeial Convention, includes quality specifications for atropine sulfate.
- European Pharmacopoeia, published by the Council of Europe's European Directorate for the Quality of Medicines & HealthCare, includes quality specifications for atropine sulfate.
- Which of these standards and regulation hold for the sense of atropine this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Treatment of symptomatic bradycardia in appropriate clinical settings.
- Antidotal treatment of muscarinic effects of organophosphate and other cholinesterase inhibitor poisoning.
- Ophthalmic dilation of the pupil and paralysis of accommodation.
- Reduction of salivary and respiratory secretions in selected perioperative settings.
- Low-concentration ophthalmic preparations for slowing childhood myopia progression in some clinical settings.
- Which of these real-world use hold for the sense of atropine this model covers, and on what evidence? provenance
Typical measurements
Recalled without web access and unsourced; every item is a lead to verify.
- Molar mass of atropine free base - 289.37 - g/mol
- Which of these typical measurements hold for the sense of atropine this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Excess exposure can cause an antimuscarinic toxidrome, including dry mouth, dilated pupils, tachycardia, urinary retention, delirium and hyperthermia.
- Reduced sweating can impair heat dissipation.
- Pupillary dilation can precipitate acute angle closure in susceptible eyes.
- Ophthalmic administration can produce systemic toxicity, particularly in children.
- In cholinesterase inhibitor poisoning, atropine does not directly reverse nicotinic neuromuscular weakness.
- Which of these failure modes and hazards hold for the sense of atropine this model covers, and on what evidence? provenance
Regional variation
Recalled without web access and unsourced; every item is a lead to verify.
- Approved indications, available formulations and prescription requirements vary by jurisdiction.
- Regulatory approval and clinical use of low-concentration atropine for myopia control vary by country.
- Which of these regional variation hold for the sense of atropine this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Hyoscyamine - Medicinal hyoscyamine is the levorotatory enantiomer; atropine is the racemic mixture.
- Scopolamine - A distinct tropane antimuscarinic alkaloid with an additional oxygen bridge and a different clinical effect profile.
- Atropine sulfate - A salt form of atropine, commonly used in medicines, rather than a different active alkaloid.
- Pralidoxime - An oxime that can reactivate inhibited acetylcholinesterase under suitable conditions; atropine instead blocks muscarinic receptors.
- Atropa belladonna - A plant containing tropane alkaloids, rather than the isolated chemical substance.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of atropine this model covers, and on what evidence? provenance
What the second pass must settle
- Does an existing Vercy world model already cover atropine, requiring this registry entry to link to it?
- Which authoritative chemical identifiers unambiguously distinguish racemic atropine, its individual enantiomers and its salt forms?
- Which analytical methods and acceptance limits adequately establish racemic composition and distinguish relevant tropane alkaloids?
- Which current monographs establish form-specific assay, impurity and stability requirements for the materials this catalogue will encounter?
- How should the registry connect atropine sulfate and individual medicinal products without duplicating the atropine substance model?